Market Intelligence Ecosystem
Aurobindo Pharma Limited (NSE:AUROPHARMA) Q3 FY23 Earnings Concall dated Feb. 10, 2023. Corporate Participants: Deepti Thakur -- Investor Relations Santhanam Subramanian -- Chief Financial Officer Satakarni
Fortis Healthcare Limited (NSE: FORTIS) reported a Revenue from Operations of ₹1,559.88 Crores, an increased of 6% growth from the previous year.
Piramal Pharma Ltd (NSE: PPLPHARMA) Q3 FY23 Earnings Concall dated Feb. 09, 2023 Corporate Participants: Gagan Borana -- General Manager, Investor Relations and Sustainability
MedPlus Health Services Ltd (NSE:MEDPLUS) Q3 FY23 Earnings Concall dated Feb. 06, 2023. Corporate Participants: Prasad Reddy Battinapatla -- Assistant Financial Controller Gangadi Madhukar
AMI Organics Ltd (NSE: AMIORG) Q3 FY23 Earnings Concall dated Feb. 04, 2023 Corporate Participants: Bhavin Shah -- Chief Financial Officer Nareshkumar Patel -- Chief Executive
Aarti Industries Ltd (NSE: AARTIIND) Q3 FY23 Earnings Concall dated Feb. 06, 2023 Corporate Participants: Nishid Solanki -- Investor Relations Rajendra Gogri -- Chairman and Managing
Zydus Lifesciences Ltd (NSE:ZYDUSLIFE) Q3 FY23 Earnings Concall dated Feb. 03, 2023. Corporate Participants: Ganesh N. Nayak -- Executive Director Sharvil P. Patel -- Managing Director
Emami Limited (NSE:EMAMILTD) Q3 FY23 Earnings Concall dated Feb. 03, 2023. Corporate Participants: Mohan Goenka -- Vice Chairman & Whole-Time Director Gul Raj Bhatia -- President,
Divi's Laboratories Ltd (NSE: DIVISLAB) Q3 FY23 Earnings Concall dated Feb. 03, 2023 Corporate Participants: M. Satish Choudhury -- Company Secretary and Chief Investor
Max Healthcare Institute Ltd.’s gross revenue in Q3FY23 rose 13% to ₹ 1,559 crores. Consolidated Profit After Tax came at ₹ 269
Hester Biosciences Limited (NSE:HESTERBIO) Q3 FY23 Earnings Concall dated Jan. 31, 2023. Corporate Participants: Rajiv Gandhi -- Chief Executive Officer and Managing Director Priya
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) Q3 FY23 Earnings Concall dated Jan. 31, 2023 Corporate Participants: Abhishek Sharma -- Head of Investor Relations and
Key highlights from Torrent Pharmaceuticals Ltd (TORNTPHARM) Q3 FY23 Earnings Concall Management Update: [00:05:39] TORNTPHARM said the company expects to file about
Torrent Pharmaceuticals Ltd (NSE: TORNTPHARM) Q3 FY23 Earnings Concall dated Jan. 25, 2023 Corporate Participants: Sudhir Menon -- Executive Director, (Finance) and Chief Financial
Indoco Remedies Limited (NSE: INDOCO) Q3 FY23 Earnings Concall dated Jan. 24, 2023 Corporate Participants: Aditi Panandikar -- Managing Director Sundeep V. Bambolkar -- Joint Managing
Granules India Ltd (NSE: GRANULES) Q3 FY23 Earnings Concall dated Jan. 24, 2023 Corporate Participants: Irfan Raeen -- Investor Relation Advisor Krishna Prasad Chigurupati -- Chairman
Syngene International Ltd (NSE: SYNGENE) Q3 FY23 Earnings Concall dated Jan. 24, 2023 Corporate Participants: Avantika Mishra -- Associate - EY Jonathan Hunt -- Managing Director
Syngene International Ltd (NSE: SYNGENE) Q3 FY23 Earnings Concall dated January 24, 2023 Corporate Participants: Avantika Mishra -- Associate - EY Jonathan Hunt -- Managing Director
Gland Pharma Limited (NSE:GLAND) Q3 FY23 Earnings Concall dated Jan. 23, 2023. Corporate Participants: Sumanta Bajpayee -- Vice President, Finance and Investor Relations Srinivas
“Our hospital business is on a very strong growth trajectory and will continue to grow. We will improve not only in revenues
Shalby Ltd.‘s revenues in Q2FY23 rose 11% to ₹ 2,018 millions. Consolidated Profit After Tax came at ₹ 184 millions showcasing a